Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 4/2023

26-05-2023 | Ovarian Cancer | Original Research Article

Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA

Authors: David Elsea, Dominic Muston, Lin Fan, Adela Mihai, Yang Meng, Adam Kasle, Matthew Monberg

Published in: Targeted Oncology | Issue 4/2023

Login to get access

Abstract

Background

Poly(ADP-ribose) polymerase inhibitor maintenance treatments are available for platinum-sensitive advanced ovarian cancer. Olaparib (O) is available for BRCA mutation patients or in combination with bevacizumab (O+B) for patients with homologous recombination deficiency (HRD+); niraparib (N) is available for all patients.

Objective

This study aimed to evaluate the cost effectiveness of biomarker testing and maintenance treatments (mTx) with poly(ADP-ribose) polymerase inhibitor in platinum-sensitive advanced ovarian cancer in the USA.

Patients and Methods

Ten strategies were evaluated (S1–S10), representing biomarker testing (none, BRCA or HRD), and mTx (O, O+B, N or B). PAOLA-1 data were used to build a model estimating progression-free survival (PFS), second PFS (PFS2) and overall survival for O+B. PFS was modelled through mixture cure models; PFS2 and overall survival were modelled by standard parametric models. Hazard ratios of PFS for O+B versus B, N and O were obtained from the literature to estimate PFS for B, N and O. PFS2 and OS for B, N and O were informed by PFS benefits.

Results

S2 (no testing, B) had the lowest cost while S10 (HRD testing, O+B for HRD+ and B for HRD−) had the highest quality-adjusted life-years (QALYs). All niraparib strategies were dominated. S2, S4 (BRCA testing, O for BRCA+ and B for BRCA−), S6 (BRCA testing, olaparib plus bevacizumab for BRCA+ and bevacizumab for BRCA−) and S10 were the non-dominated strategies with an incremental cost-effectiveness ratio of $29,095/QALY, $33,786/QALY and $52,948/QALY for S4 versus S2, S6 versus S4 and S10 versus S6, respectively.

Conclusions

Homologous recombination deficiency testing followed by O+B for HRD+ and B for HRD− is a highly cost-effective strategy for patients with platinum-sensitive advanced ovarian cancer. A HRD biomarker-guided approach provides most QALYs with good economic value.
Appendix
Available only for authorised users
Literature
1.
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–36.CrossRefPubMedPubMedCentral
2.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.CrossRefPubMed
3.
Gonzalez Martin A, Oza AM, Embleton AC, Pfisterer J, Ledermann JA, Pujade-Lauraine E, et al. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecol Oncol. 2019;152(1):53–60.CrossRefPubMedPubMedCentral
4.
Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–505.CrossRefPubMed
5.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–28.CrossRefPubMed
6.
González-Martín A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–402.CrossRefPubMed
7.
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.CrossRefPubMed
8.
Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol. 2016;27(8):1449–55.CrossRefPubMed
9.
10.
Kantar. CancerMPact® treatment architecture U.S., ovarian cancer. 2019.
11.
Penn CA, Wong MS, Walsh CS. Cost-effectiveness of maintenance therapy based on molecular classification following treatment of primary epithelial ovarian cancer in the United States. JAMA Netw Open. 2020;3(12): e2028620.CrossRefPubMedPubMedCentral
12.
Muston D, Hettle R, Monberg M, McLaurin KK, Gao W, Swallow E, et al. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. Gynecol Oncol. 2020;159(2):491–7.CrossRefPubMed
13.
Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, et al. A critical appraisal and recommendations for cost-effectiveness studies of poly(ADP-ribose) polymerase inhibitors in advanced ovarian cancer. Pharmacoeconomics. 2020;38(11):1201–8.CrossRefPubMedPubMedCentral
14.
Gonzalez R, Havrilesky LJ, Myers ER, Secord AA, Dottino JA, Berchuck A, et al. Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer. Gynecol Oncol. 2020;159(2):483–90.CrossRefPubMedPubMedCentral
15.
Simmons D, Bhalla J, Stone R, Engstrom-Melnyk J, McLaurin K. Clinical outcomes and cost associated with HRD biomarker guided first line maintenance therapy in advanced ovarian cancer. Gynecol Oncol. 2021;162:S111–2.CrossRef
16.
17.
Elsea D, Fan L, Mihai A, Moustaid FE, Simmons D, Monberg M, et al. Cost-effectiveness analysis of olaparib in combination with bevacizumab compared with bevacizumab monotherapy for the first-line maintenance treatment of homologous recombination deficiency-positive advanced ovarian cancer. Pharmacoeconomics Open. 2022;6(6):811–822.
18.
Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F, et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931–41.CrossRefPubMed
19.
20.
21.
Hettle R, McCrea C, Lee CK, Davidson R. Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer. Ther Adv Med Oncol. 2021;13:17588359211049640.CrossRefPubMedPubMedCentral
22.
Vergote I, Ray-Coquard I, Anderson DN, Cantuaria G, Colombo N, Garnier-Tixidre C, et al. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer. 2021;157:415–23.CrossRefPubMed
23.
24.
Phillippo DM, Ades AE, Dias S, Palmer S, Abrames KR, Welton NJ. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. Sheffield: School of Health and Related Research, University of Sheffield; 2016.
25.
Ray-Coquard I, Leary A, Pignata S, Cropet C, Martin AG, Bogner G, et al. Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC). Ann Oncol. 2022;33:S1396–7.CrossRef
26.
Martin AG, Pothuri B, Vergote I, Graybill W, Mirza M, Mccormick C, et al. 530P PRIMA/ENGOT-OV26/GOG-3012 study: updated long-term PFS and safety. Ann Oncol. 2022;33:S789.CrossRef
27.
DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 Trial. J Clin Oncol. 2022;41(3):609–617.
28.
Fang CY, Frosch ZA. Understanding and addressing cancer care costs in the United States. JAMA Netw Open. 2021;4(10): e2127964.CrossRefPubMed
29.
Metadata
Title
Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA
Authors
David Elsea
Dominic Muston
Lin Fan
Adela Mihai
Yang Meng
Adam Kasle
Matthew Monberg
Publication date
26-05-2023
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 4/2023
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-023-00966-6

Other articles of this Issue 4/2023

Targeted Oncology 4/2023 Go to the issue

Correction

Correction to: Relugolix: A Review in Advanced Prostate Cancer

Original Research Article

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors

Original Research Article

Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis

Original Research Article

ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study

Original Research Article

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

Original Research Article

Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits